
AstraZeneca Plc (NASDAQ:AZN) on Thursday reported third-quarter 2025 sales of $15.19 billion, up 12% year over year (+10% at constant currency), beating the consensus of $14.80 billion, driven by double-digit growth in oncology, CVRM, and biopharmaceuticals.
The company’s adjusted EPADS reached $1.19, beating the consensus of $1.14. The adjusted EPS was $2.38 (1 ADR = 2 Common Shares).